Q-omics provides the consensus-scored C2orf50 profile across patient tissues and cancer cell-line models. C2orf50 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, C2orf50 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, C2orf50 RNA expression shows 16,566 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight COAD, KIRC, and KIRP as cancer lineages where C2orf50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2orf50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2orf50 survival associations across molecular data types. C2orf50 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2orf50 RNA expression–survival associations across cancer types. High C2orf50 expression shows unfavorable associations in COAD and LGG, but favorable associations in BRCA, KIRC, THYM and MESO. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for C2orf50 RNA expression.
This table summarizes C2orf50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C2orf50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2orf50 shows lower tumor expression in KIRC, THCA, LUSC and LUAD and higher tumor expression in BRCA and STAD. The KIRC box plot shows higher C2orf50 RNA expression in normal versus tumor tissue (log2 FC = −0.326, t-test p < 0.001).
This table shows molecular features associated with C2orf50 in patient tissues and cancer cell lines. In patient samples, C2orf50 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C2orf50 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
